PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10534471-7	1999	Oral bosentan, a mixed ET-1 receptor antagonist, was administered after virus inoculation in doses of 0 (control group), 10, or 100 mg. kg(-1).	Bosentan	5-13	endothelin 1	Mus musculus	23-27	
20690805-1	2010	We investigated the effects of the endothelin-1 (ET-1) receptor dual antagonist (Bosentan ) on the inflammatory cytokines and the chemoattractant molecules associated with breast cancer growth and the development of tumor infiltration in bone explants.	Bosentan	81-89	endothelin 1	Mus musculus	35-47	
34840823-8	2021	Bosentan inhibited ET-1 expression in plasma (P < 0.05) and RPE/choroid/sclera complexes at P28 in rd10 mice.	Bosentan	0-8	endothelin 1	Mus musculus	19-23	
32535962-9	2021	Histologically, the number of infiltrated dermal cells, the epidermal EDN1 expression, and the number of intraepidermal nerve fibers were significantly inhibited upon bosentan application.	Bosentan	167-175	endothelin 1	Mus musculus	70-74	
32561219-8	2020	FPI-induced expression levels of ET-1 and ETB receptors were reduced by bosentan, but not by ambrisentan.	Bosentan	72-80	endothelin 1	Mus musculus	33-37	
32561219-9	2020	In cultured mouse astrocytes and brain microvessel endothelial cells, ET-1 (100 nM) increased prepro--ET-1 mRNA, which was inhibited by bosentan, but not by ambrisentan.	Bosentan	136-144	endothelin 1	Mus musculus	70-74	
32561219-9	2020	In cultured mouse astrocytes and brain microvessel endothelial cells, ET-1 (100 nM) increased prepro--ET-1 mRNA, which was inhibited by bosentan, but not by ambrisentan.	Bosentan	136-144	endothelin 1	Mus musculus	102-106	
22320712-7	2012	Treatment with the non-selective ET(A)/ET(B) receptor antagonist bosentan, and selective ET(A) or ET(B) receptor antagonists BQ-123 or BQ-788, respectively, inhibited ET-1- and ovalbumin-induced neutrophil migration to the peritoneal cavity.	Bosentan	65-73	endothelin 1	Mus musculus	167-172	
22320712-9	2012	The ET-1- and ovalbumin-induced neutrophil recruitment were reduced in TNFR1 deficient mice, and by treatments targeting CXCL1 or CXC chemokine receptor 2 (CXCR2); further, treatment with bosentan, BQ-123, or BQ-788 inhibited ET-1- and antigen-induced production of TNFalpha and CXCL1.	Bosentan	188-196	endothelin 1	Mus musculus	4-8	
22320712-9	2012	The ET-1- and ovalbumin-induced neutrophil recruitment were reduced in TNFR1 deficient mice, and by treatments targeting CXCL1 or CXC chemokine receptor 2 (CXCR2); further, treatment with bosentan, BQ-123, or BQ-788 inhibited ET-1- and antigen-induced production of TNFalpha and CXCL1.	Bosentan	188-196	endothelin 1	Mus musculus	226-230	
30185506-5	2018	Rapamycin, an mTORC1 inhibitor, and bosentan, an EDN1 antagonist, eliminated the difference in renal function between TSC1fl/fl and Fibro-TSC1-/- mice after LPS injection.	Bosentan	36-44	endothelin 1	Mus musculus	49-53	
26883974-8	2016	HT22 cells synthesize high levels of ET-1 in normal conditions, which was reduced with palmitate and bosentan as well as low and high glucose conditions.	Bosentan	101-109	endothelin 1	Mus musculus	37-41	
25660617-2	2015	In a murine doxorubicin cardiotoxicity model, increased endothelin-1 (ET-1) expression and cardioprotective effects of the dual ET-1 blocker bosentan were demonstrated.	Bosentan	141-149	endothelin 1	Mus musculus	128-132	
21547665-6	2011	In the experiment to assess prevention of endothelin-1-induced sudden death in mice, compound 5b showed comparable activity to bosentan, and 30 was more potent than bosentan.	Bosentan	165-173	endothelin 1	Mus musculus	42-54	
20690805-1	2010	We investigated the effects of the endothelin-1 (ET-1) receptor dual antagonist (Bosentan ) on the inflammatory cytokines and the chemoattractant molecules associated with breast cancer growth and the development of tumor infiltration in bone explants.	Bosentan	81-89	endothelin 1	Mus musculus	49-53	
17341678-10	2007	Treatment of mice with bosentan (endothelin-1 receptor antagonist) normalized the coronary perfusion pressure, demonstrating that the elevated endothelin-1 release was sufficient to account for the increased coronary perfusion pressure.	Bosentan	23-31	endothelin 1	Mus musculus	33-45	
17334537-10	2007	In vitro, pre-incubation with ET-1 (0.1 microM) 4 h before infection enhanced the uptake of the parasites by peritoneal macrophages, and this effect was abrogated when macrophages were pre-treated with bosentan (1 microM) 15 min before incubation with ET-1.	Bosentan	202-210	endothelin 1	Mus musculus	30-34	
17334537-10	2007	In vitro, pre-incubation with ET-1 (0.1 microM) 4 h before infection enhanced the uptake of the parasites by peritoneal macrophages, and this effect was abrogated when macrophages were pre-treated with bosentan (1 microM) 15 min before incubation with ET-1.	Bosentan	202-210	endothelin 1	Mus musculus	252-256